American Association for Cancer Research (AACR) 2024: TEAD1/4 inhibitors exhibit deeper biological impact and broader activity compared to TEAD1-only inhibitors in both monotherapy and combination without additional kidney toxicity
Apr 12, 2024
View Presentation